The pS2 promoter is complex with binding sites for a number of protein factors that may participate in modulating its activity. The pS2 gene was transcriptionally activated by estrogens in HepG2 cells transformed (HepER3) to express the estrogen receptor ␣ (ER␣). The phorbol ester phorbol 12-myristate 13-acetate (PMA) stimulated pS2 expression in both HepER3 and the parental, non-ER-expressing HepG2 cells, although its activity was substantially less in HepG2 cells. The use of selective protein kinase inhibitors suggested that the MAPK pathway contributes substantially to estrogen stimulation of the pS2 promoter. The activator protein 1 (AP1) site at Ϫ332 to Ϫ338 in the pS2 promoter had a dominant role in the response to both estrogens and PMA, although the estrogen response element at Ϫ393 to Ϫ405 was essential to mediate the response to estrogen. The potentiation of pS2 promoter activity by the AP1 motif in response to estrogen was dependent on the ligand binding domain of ER␣. Furthermore, the presence of an intact AP1 element in the pS2 promoter sustained suppression of pS2 promoter activity by an LXXLL peptide. In summary, the data suggest that the effect of estrogen is mediated through a cross-talk between the estrogen-responsive element and the AP1 response element and that ER␣ plays a crucial role in mediating the effect of both estrogen and PMA.
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Estrogens exert their gene regulatory function through the estrogen receptor (ER). Presently, two subtypes of the ER have been identified, the ␣ subtype (ER␣) (Green et al., 1986) and the recently discovered ␤ subtype (ER␤) (Kuiper et al., 1996) . The ERs belong to a superfamily of nuclear receptors that also includes the steroid receptors for androgens, glucocorticoids, mineralocorticoids, and progestins; the receptors for vitamin A and D; the thyroid hormone receptors; and a number of orphan receptors for which no ligands have yet been identified. The nuclear receptors are structurally related proteins that function as ligand-dependent transcription factors, playing a crucial role in the endocrine signaling pathways. The ligand-activated homo-or heterodimerized receptors interact specifically and with relatively high affinity with regulatory DNA sequences, so-called hormone response elements, found predominantly in the promoter region upstream of the coding sequences of target genes. After binding of ligand, the receptor 3D structure is transformed to adopt an agonist or antagonist conformation depending on the type of ligand bound (Brzozowski et al., 1997; Shiau et al., 1998) . The agonist structure of ER␣ has been shown to expose the activation function-2 (AF-2) (Tora et al., 1989b) in the ligand binding domain (LBD) and permits interaction with coactivators (Shiau et al., 1998) , whereas, in the antagonist structure, AF-2 is translocated to a different position that may permit interaction with corepressors but not coactivators (Brzozowski et al., 1997; Shiau et al., 1998; Smith et al., 1997) .
The ERs are best known for their gene modulatory effect via binding to estrogen responsive elements (ERE) on DNA. Lately several alternative regulatory pathways have been described that include response elements to which the ERs do not bind directly. Genes regulated by ERs via the indirect pathway include the ovalbumin, the IGF-1 and the collagenase genes (Gaub et al., 1990; Umayahara et al., 1994; Webb et al., 1995) . These genes are activated by the ERs via AP1 sites that bind the dimeric transcription factor AP1, com-posed of members of the Jun and Fos families (Angel and Karin, 1991) . Apparently, the ER is not in direct contact with the AP1 response element; rather, it seems to be tethered to the DNA via the transcription factor/coactivator complex that contacts the AP1 site (Kushner et al., 2000) . Similar mechanisms of ER action have been described for other transcription factors (Saville et al., 2000) , which, at least in part, may explain the diversity of the estrogen response of various target genes and tissues.
In addition to the conventional activation of the ERs by natural or synthetic hormones, alternative activation pathways by various effectors, including a number of mitogenic growth factors, have been described. The epidermal growth factor-1 has been shown to induce phosphorylation of serine residues in the N-terminal A/B domain of ER␣ (Kato et al., 1995) that resulted in enhanced activity of the ligand independent activation function-1 (AF-1) within the A/B domain (Tora et al., 1989b) . Recently, an AF-1 specific coactivator was described whose interaction with the AF-1 of ER␣ was regulated by phosphorylation of serine 118 in the A/B domain of ER␣ (Endoh et al., 1999) . Whether a similar mechanism is important for the transcriptional response to various growth factors of complex natural promoters such as those of the estrogen-regulated pS2 and cathepsin D genes is not known. However, in the MCF-7 breast cancer cell line, growth factor stimulation of the pS2 and cathepsin D genes has been shown to be suppressed by antiestrogens, suggesting that the growth factor effect was mediated through the ER pathway (Chalbos et al., 1993) .
The pS2 gene product is a well-known estrogen inducible protein previously shown to be expressed in breast and gastrointestinal tissues (Rio et al., 1987 (Rio et al., , 1988 . Its expression has been considered an indication that breast tumor cells express ER and that the tumor therefore would be responsive to antiestrogen therapy. The biological role of pS2 is not very well understood. However, a function for pS2 in stimulating mucosal repair has been reported (Playford et al., 1996) . The pS2 response to estrogen has previously been demonstrated to be mediated through an imperfect ERE at nucleotides Ϫ405 to Ϫ393 in the pS2 promoter (Berry et al., 1989) . Furthermore, gel retardation experiments with extracts derived from MCF-7 cells, using the pS2 promoter fragment as a bait, revealed multiprotein complexes composed of ER␣ and a protein immunologically related to c-fos (Schuh and Mueller, 1993) . Interestingly, in the vicinity of the ERE, the pS2 promoter contains an AP1 response element at nucleotides Ϫ338 to Ϫ332. This may suggest that AP1, in addition to ER, participates and exercises control of pS2 gene transcription, and that multiple signaling pathways are involved.
The present study was undertaken to determine whether AP1, together with ER␣, plays a central role in the regulation of the pS2 promoter. We have found that the pS2 gene is expressed in hepatocarcinoma cells (HepG2) (Barkhem et al., 1997) . In the present study, we have investigated the effect of estrogen and PMA on the pS2 promoter in the context of HepG2 cells, either in the presence or absence of ER␣. We have determined the relative influence of the ERE and the adjacent AP1 motif in the pS2 promoter on the regulation of the pS2 gene and revealed a cross-talk between these elements in response to estrogen. Furthermore, we have unraveled signal transduction pathways that converge on the pS2 promoter by the use of selective protein kinase inhibitors.
Experimental Procedures
Materials. Moxestrol (R2858) was purchased from PerkinElmer Life Sciences (Boston, MA); tamoxifen and phorbol 12-myristate 13-acetate (PMA) were from Sigma (St. Louis, MO). Bisindolylmaleimide, LY 294002, and PD 98059 were from Calbiochem (La Jolla, CA). ICI 164,384 was synthesized according to the published procedure (Bowler et al., 1989) . The minimal essential cell culture media, fetal calf serum (FCS), nonessential amino acids, sodium pyruvate, L-glutamine, OptiMEM, lipofectin, G418, and gentamycin were purchased from Invitrogen (Carlsbad, CA). Phenol red-free Coon's/F12 medium was from SVA (Uppsala, Sweden). SHBG-dissociative enhanced lanthanide fluorescence immunoassay was purchased from PerkinElmer Wallac (Turku, Finland) and the ELSA-pS2 assay kit was from CIS Bio International (Gif-sur-Yvette, France). The chemiluminescence substrate disodium 3-[4-methoxyspiro(1,2-dioxetane-3,2Ј-(5Ј-chloro)tricyclo[3.3.1.1]decan-4-yl]phenyl phosphate) (CSPD) and the Saphire enhancement solution were purchased from PerkinElmer Life Sciences. Oligonucleotides were synthesized by CyberGene AB (Huddinge, Sweden).
Choice of Estrogen Agonist. We have preferred to use the synthetic estrogen analog moxestrol rather than estradiol (E2) in the hormone induction experiments because estradiol is readily metabolized in the liver cells. Moxestrol exhibited the same characteristics as E2 regarding induction of the pS2 gene in the HepER3 cells except for an approximately 10-fold leftward shift in the EC 50 value relative to E2 (data not shown).
Vector Constructs. The vector used for generation of the HepER3 cell line has been described previously (Barkhem et al., 1997) . The vector pS2-CAT/pML2 (a kind gift from P. Chambon) was reconstructed as follows: the HindIII-EcoRI fragment containing the chloramphenicol acetyl transferase reporter gene and simian virus 40 poly(A) signal was replaced by the cDNA encoding the secreted form of placental alkaline phosphatase (ALP) and the human growth hormone poly(A) signal, ligated into the corresponding sites. The resulting vector was designated pS2-ALP. The pS2 mut ERE-ALP (mutERE) was constructed by introducing the ERE mutated oligonucleotide 5ЈCCTTCCCTTCCCCCTGCAATACTCGAGCATATACCCC-3Ј (upper strand; mutated nucleotides are underlined) into the SacIDraIII sites at the positions Ϫ429 and Ϫ393, respectively, in the wildtype pS2 promoter (Berry et al., 1989) . The vector pS2 mut AP1-ALP (mutAP1) was obtained by insertion of the AP1-mutated oligonucleotide 5ЈGTGAGCCACTGTTGTCAGGCCAAGCCTTTTTCCGGCCATCTCT-CACTACTCGAGCCTTCTGCA-3Ј (upper strand; mutated nucleotides are underlined) into the DraIII-PstI sites at positions Ϫ393 and Ϫ328, respectively, in the wild-type pS2 promoter (Berry et al., 1989) . The vector pS2 mut ERE mut AP1-ALP (mutERE mutAP1) was constructed by insertion of the ERE and AP1 mutated oligonucleotide 5ЈCCTTCC-CTTCCCCCTGCAATACTCGAGCATATACCCCGTGAGCCACTG-TTGTCAGGCCAAGCCTTTTTCCGGCCATCTCTCACTACTCGA-GCCTTCTGCA-3Ј into the SacI-PstI sites at Ϫ429 and Ϫ328, respectively (upper strand; mutated nucleotides are underlined).
The vectors pS2(EREvit)-ALP and pS2(EREvit) mutAP1 were constructed by insertion of oligonucleotides into the SacI-PstI sites. The oligonucleotides encompass a vitellogenin estrogen-responsive element [ERE(vit)] and an intact or mutated AP1 element in the context of wild-type pS2 promoter sequence. The cDNA encoding the fulllength human ER␣ (Green et al., 1986) was cloned into the BamHI and the XbaI sites in the mammalian expression vector pMT-hGH after excision of the human growth hormone coding sequences. The resulting expression vector for ER␣ was designated pMT-ER␣.
The HEO vector expressing ER␣ mutated at amino acid 400 (Gly to Val) has been described previously (Tora et al., 1989a) . The ER AD and ER CF constructs correspond to HE 15 and HE 19 (Kumar et al., 1987) , except that the wild-type ER␣ containing glycine at amino acid 400 was used. The Gal4DBD (pM) expression vector is a product of BD Biosciences Clontech (Paolo Alto, CA). The Gal4DBD-LXXLL peptide (␣␤ ⌱) expression vector has been described previously .
Cell Cultures. HepG2 cells (American Type Culture Collection, Manassas, VA) and the HepER3 cells (Barkhem et al., 1997) were cultured in minimum essential medium supplemented with 10% FCS, 1% nonessential amino acids, 1 M sodium pyruvate, and 2 mM L-glutamine. All cell cultures were maintained at 37°C in humidified chambers at 5% CO 2 Transient DNA Transfections. All transient transfections were performed using the OptiMEM/lipofectin procedure according to the suppliers' recommendations (Invitrogen). Transient transfections of the HepER3 cells and the HepG2 cells were performed in 48-well plates after seeding of 50 ϫ 10 3 cells/cm 2 in phenol red free Coon's/ Ham's F12 media supplemented with 1% FCS (double dextran charcoal-stripped), 2 mM L-glutamine, and 50 g/ml gentamycin 24 h before transfection. Cells were transfected for 6 h with 0.2 g of DNA/well of the different pS2-ALP reporter constructs. In some experiments, 0.1 g of DNA/well of a vector expressing the ER␣ variant HEO (Tora et al., 1989a) HepG2 or HepER3 cells were seeded per well in 96-well plates in 100 l of Coon's/Ham's F12 media supplemented with 1% FCS (double dextran charcoal-stripped), 2 mM L-glutamine and 50 g/ml gentamycin. Twenty-four hours later, cells were rinsed and refed with the same medium supplemented with hormone (moxestrol, tamoxifen, or ICI 164,384) or PMA. Cells were exposed for hormone or PMA for 72 h (except for transiently transfected cells, which were exposed for 48 h) before being harvested and analyzed for effect on gene expression. Triplicates of each concentration of hormone or PMA were performed in all experiments, which also were repeated several times. Conditioned medium was analyzed for the levels of pS2 and SHBG was expressed using an ELSA-pS2 immunoassay and SHBGDelfia, respectively, following the supplier's instructions. All experiments presented were performed in triplicate and repeated at least three times. The results presented in the figures are representative for all experiments performed.
Assay for Human Placental Alkaline Phosphatase. The level of human ALP expressed from the various pS2-reporter constructs was determined by a chemiluminescence assay as follows. After heat inactivation of the conditioned culture medium for 15 min at 65°C, a 10-l aliquot was mixed with 200 l of assay buffer (10 mM diethanolamine, pH 10.0, 0.1 mM MgCl 2 , and 0.5 mM CSPD) in white microtiter plates (Dynatech Laboratories In Vitro AB, Stockholm, Sweden) and incubated at 37°C for 20 min before being transferred to a 96-well luminometer (Luminoskan; Labsystems, Helsinki, Finland) for integral measurement with 1-s reading per well. The ALP activity is expressed in light units and is directly proportional to the level of ALP expressed in the cells.
Assessment of Cytotoxicity. To assess the content of viable cells in dose-response or transient transfection experiments, the bioreduction of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymetoxy-phenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (Promega, Madison, WI) to formazan by dehydrogenase enzymes found in metabolically active cells was measured at 490 nm and 650 nm (Cory et al., 1991) .
Calculation of Normalized Response. In Fig. 9A , HepG2 cells were cotransfected with ER␣ (HEO) together with the pS2-ALP reporter vector and increasing amounts of the expression vector for the Gal4DBD-LXXLL-peptide fusion. Normalized response was obtained by dividing the ALP activity of the reporter vector with the value obtained in the cytotoxicity assay described above, which measures viable cell activity. In Fig. 9B , HepG2 cells were cotransfected with ER␣ (HEO) and pS2(EREvit)-ALP or pS2(EREvit) mutAP1-ALP together with increasing amounts of the expression vector for the Gal4DBD-LXXLL-peptide fusion or the Gal4DBD expression vector. Normalized response was obtained as in Fig. 9A . However, the responses are expressed as the ratio of the normalized ALP activity evoked by cells transfected with Gal4DBD-LXXLL fusion and cells transfected with an equivalent amount of the empty Gal4DBD expression vector, respectively.
Results
Induction of the pS2 and SHBG Genes in HepG2/ HepER3 Cells. The response to the synthetic estrogen moxestrol or the phorbol ester PMA on the expression of the endogenous pS2 and SHBG genes in HepG2 cells, in the presence or absence of estrogen receptor expression, was examined. We have used the human hepatocarcinoma cell line HepG2, which lacks endogenous expression of ER␣ and -␤ (data not shown) and HepG2 cells stably transformed to express ER␣ (HepER3) (Barkhem et al., 1997) to assess the role of ER␣ on SHBG and, in particular, pS2 gene regulation. In the presence of ER␣, both moxestrol and PMA showed a stimulatory effect on pS2 gene expression but with different potency and efficacy (Fig. 1A) . PMA displayed the most efficacious response on pS2 expression, exceeding the response to moxestrol. In the non-ER-expressing HepG2 cells, only PMA had a stimulatory effect on pS2 gene expression (Fig.  1B) . The response to PMA in the HepG2 cells was at least 10-fold lower compared with its effect in the ER␣ expressing HepER3 cells, suggesting that the presence of ER␣ potentiated the effect of PMA. Only moxestrol, in contrast to PMA, stimulated expression of the estrogen-responsive SHBG gene in HepER3 (Fig. 1C) . Thus, ligand-independent activation of estrogen inducible genes in these liver cells does not seem to be a general phenomenon; rather, it is restricted to specific genes (e.g., the pS2 gene). We also examined the combined effect of moxestrol and PMA in HepER3 cells, which resulted in strong synergism with a pS2 expression level severalfold higher than would be predicted by the sum of the expression levels induced by PMA or moxestrol alone (Fig. 1D) . The synergistic effects were effectively blocked by the pure antiestrogen ICI 164,384, which also antagonized the individual responses of the effectors on pS2 expression (Fig. 1D) , emphasizing the importance of ER␣ in both events. As expected, no synergism was observed in the parental ER␣-deficient HepG2 cells (data not shown).
Effects of Selective Protein Kinase Inhibitors on pS2 Gene Expression. To dissect the role of different signal transduction pathways for estrogen or PMA activation of pS2 expression in HepER3 cells, selective protein kinase inhibitors were used. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor PD 98059 blocked moxestrol stimulated pS2 expression, suggesting a role of the extracellular-signal regulated family of mitogen-activated protein kinases (MAPK) in the estrogen effect on pS2 gene expression (Fig. 2) . Furthermore, the phosphoinositide 3-kinase (PI3K) inhibitor LY 294002 also suppressed pS2 expression in response to moxestrol, whereas the protein kinase C inhibitor bisindolylmaleimide had only a modest effect, if any. In contrast, PMA induction of pS2 was effectively blocked by bisindolylmaleimide, which, as anticipated, sug- (Fig. 2) . Interestingly, the effect of MAPK seems to be cell-specific with respect to estrogen induction of the pS2 gene because PD 98059 did not affect estrogen stimulation of the pS2 gene in the breast cancer cell line, ZR-75-1 (data not shown). To exclude that the effects of the different inhibitors were caused by unspecific cytotoxicity, the concentrations of inhibitors were chosen such that a cytotoxicity marker (Cory et al., 1991) was unaffected at the doses used in the experiments (data not shown). Furthermore, SHBG protein levels were not reduced by any of the different inhibitors (data not shown).
Role of the ERE and AP1 Response Elements in Response to Estrogen or PMA. Because both PMA and MAPK signal transduction pathways may converge on AP1 response elements, we decided to investigate the function of the AP1 motif adjacent to the ERE in the pS2 promoter. To examine the individual and combined importance of the ERE and the AP1 motif in the response to hormones and PMA, a mutational analysis at the promoter level was carried out.
Oligonucleotides containing mutated ERE and/or AP1 motifs were ligated into the pS2 promoter, replacing the corresponding wild-type sequences. To retain distances between different response elements within the pS2 promoter, the wildtype ERE and AP1 motifs, respectively, were substituted by the same number of nonsense nucleotides. The wild-type pS2 promoter fragment and the different mutated variants were fused to the ALP-reporter gene.
Initially, the significance of the ERE and the AP1 motifs in pS2 gene regulation in the presence of PMA was evaluated. In transient transfection experiments the various pS2 promoter constructs (Fig. 3A) were introduced into the HepER3 cells. PMA stimulated transcription from the wild-type pS2-ALP construct in the HepER3 cells (Fig. 3B) . Mutation of the ERE caused only a modest reduction in the response to PMA. However, absence of a functional AP1 motif (mutAP1) was deleterious to stimulation of gene expression by PMA.
The results of ALP expression from wild-type and mutated versions of the pS2 promoter in response to moxestrol in transient transfections of HepER3 cells is shown in Fig. 4 . As expected, in the absence of a functional ERE (mutERE) the effect of moxestrol was extinguished. Mutation of only the AP1 motif (mutAP1) also had a dramatic effect, blocking reporter gene expression in response to moxestrol to the same extent as the mutation of the ERE alone, suggesting that the ER response via the ERE is also dependent on an intact AP1 response element. Thus, the data in Fig. 4 suggest that both the ERE site and the AP1 site are important for full activity of the pS2 promoter in response to estrogen and that the presence of both sites results in more than an additive effect in the presence of ER␣.
In transient transfections of HepER3 cells with the wildtype pS2 promoter construct, both moxestrol-and PMA-induced reporter gene expression were blocked with tamoxifen (Fig. 5) . In the absence of a functional ERE, tamoxifen was still able to suppress PMA-stimulated reporter gene activity. Furthermore, tamoxifen alone displayed no agonistic activity on the pS2 gene on either intact or ERE-mutated promoter (Fig. 5) . Tamoxifen blocked the effect of PMA also in the parental HepG2 cells that lack ER␣; however, doses at least 100-fold higher than in HepER3 cells were required, indicating a non-ER-mediated mechanism (data not shown).
To further examine the role of the AP1 motif in estrogendependent pS2 promoter activation, moxestrol was titrated in transient transfection experiments in which the ER␣ variant HEO (Tora et al., 1989a) together with wild-type or AP1 mutated promoter constructs were used. The reason for using HEO, which is unstable in the absence of ligand, was simply to reduce background expression levels and thereby obtain a better signal-to-noise ratio. The pS2 promoter-reporter showed the same characteristic bell shaped titration curve in response to moxestrol (Fig. 6A) as observed for endogenous pS2 protein (Fig. 1A) . Interestingly, also the AP1 mutated construct showed a weak but significant response to moxestrol (Fig. 6B) . Furthermore, the AP1 mutated construct displayed a 10-fold lower potency for moxestrol compared with the wild-type promoter construct. Thus, the presence of the AP1 motif adjacent to the ERE potentiated pS2 promoter activity in response to estrogen with respect to both potency and efficacy. We have noticed in electrophoretic mobility shift assay experiments that the pS2 ERE has a much lower affinity for ER␣ than the consensus ERE from the vitellogenin gene (EREvit) (data not shown). To investigate whether potentiation from the AP1 motif was restricted to imperfect EREs that bind ER␣ with low affinity, the ERE of the pS2 promoter was mutated into the high-affinity EREvit (Fig.  6E) . The pS2 promoter construct containing the EREvit displayed 4-fold higher amplitude than the wild-type pS2 promoter-reporter construct and a 10-fold increase in the potency of moxestrol (Fig. 6C) . However, the high-affinity EREvit was also markedly potentiated by the presence of the AP1 motif in the pS2 promoter context (Fig. 6D ). In the absence of a functional AP1 motif, the EREvit construct displayed a decrease in reporter gene activity similar to the decrease observed for the wild-type pS2 promoter (10-versus 15-fold) and the potency of moxestrol was in both cases reduced 10-fold.
The ERE mutated pS2 promoter (mutERE) was basically unresponsive to estrogen (Fig. 4) , even when ER␣ was overexpressed (data not shown). However, we asked whether ER␣ could interact directly or indirectly with factors at the AP1 motif. Using a one-hybrid system, we demonstrated that a chimera of the transcriptional activator protein VP-16 and full-length ER␣ stimulated gene expression from the ERE mutated construct to some extent (i.e., via the AP1 motif), whereas VP16 alone had no effect (Fig. 7) . Thus, ER␣ seems to bring the chimera to the pS2 promoter despite the absence of a functional ERE, possibly by interacting with the protein complex that stimulates transcription via the AP1 motif.
The AP1 Motif Potentiates pS2 Gene Expression via the Ligand-Binding Domain of ER␣. The pS2 promoter variants containing the high-affinity EREvit and an intact or a mutated AP1 response element were cotransfected together with A/B-or EF-domain truncated ER␣ (Fig. 8, A and B) to assess the relative influence of AF-1 and AF-2 on pS2 promoter activity. In these experiments, we preferred to use pS2 promoter variants encompassing the EREvit to obtain more robust responses; however, similar results have been obtained using constructs that contain the natural ERE of the pS2 promoter (pS2-ALP and mutAP1) (data not shown). The ER␣ AD construct, which lacks the LBD but retains the N-terminal AF-1 and the DNA binding C-domain, did not respond to moxestrol in the context of the pS2 promoterreporter that contained an intact AP1 response element (Fig.  8A) . Furthermore, it displayed a significantly reduced hormone-independent activity, suggesting that AF-1 alone does not participate in pS2 promoter activation. The N-terminally truncated ER␣ CF variant encoding the DNA-and LBD was able to stimulate the pS2 promoter in the presence of moxestrol, although with a reduced activity compared with the full-length receptor (Fig. 8A) . The data suggest that the AF-2 but not AF-1 is necessary and sufficient to stimulate pS2 promoter activity although AF-1, in the context of the fulllength receptor, may synergize with AF-2 in activating the pS2 promoter to a full response. Full-length ER␣ stimulated the AP1-mutated pS2 promoter to a degree approximately 20% of the wild-type promoter (Fig. 8B) . Interestingly, neither of the truncated versions of ER␣ (ER AD and ER CF) was able to stimulate the pS2 promoter in which the AP1 motif was mutated (Fig. 8B) , suggesting that the potentiation of the pS2 promoter through the AP1 motif is mediated by the LBD of ER␣.
Suppression of pS2 Promoter Activity by an LXXLLContaining Peptide Is Modulated by the AP1 Motif.
The transcriptional activity of the AF-2 of ER␣ is dependent on its ability to interact with the p160 family of coactivators via conserved LXXLL motifs in the central region of the coactivator. To further investigate the importance of AF-2 in estrogen stimulation of the pS2 promoter, the pS2 promoterreporter-construct was cotransfected together with increasing amounts of a vector expressing an LXXLL peptide. The LXXLL peptide, which has been isolated from a phage-displayed peptide library because of its ability to interact with E2 activated ER␣ , was fused to the DNA binding domain of the yeast protein Gal4 (Gal4DBD). Overexpression of the LXXLL peptide suppressed ALP expression from the wild-type pS2 promoter in a dose-dependent fashion (Fig. 9A) , indicating that the LXXLL peptide was able to compete with and displace coactivators from the ER␣ AF-2 surface, resulting in repression of the transcription. Next, we investigated the effect of the LXXLL peptide in the context of the pS2 promoter in which the AP1 motif had been mutated. In these experiments, we preferred to use pS2 promoter variants encompassing the EREvit to obtain more robust responses. We cotransfected the pS2(EREvit)-ALP reporter construct or the pS2(EREvit) mutAP1-ALP reporter devoid of a functional AP1 element together with the full-length ER␣ (HEO) expression vector and the expression vector for the LXXLL peptide. Interestingly, larger amounts of vector expressing the LXXLL peptide were required to suppress the intact pS2 promoter compared with the construct that lacks an intact AP1 element (Fig. 9B) . In fact, the AP1 defective pS2 promoter showed approximately 30% less activity than intact pS2 promoter at an equal amount of the LXXLL peptide.
The pS2 promoter construct, in which the AP1 motif is preserved but the ERE has been mutated (mutERE), is unresponsive to estrogen (Fig. 4 and 5) . Furthermore, overexpression of the LXXLL peptide did not have any significant effect on the background expression of the mutERE reporter in the presence or absence of estrogen (data not shown). Thus, suppression studies with the LXXLL peptide cannot be performed with respect to estrogen effects. However, as shown in Fig. 3 , PMA stimulates the mutERE reporter construct. We have investigated the effect of the LXXLL peptide on PMA stimulated pS2 promoter. Neither intact nor EREmutated pS2 promoter was suppressed by overexpression of the LXXLL peptide (data not shown). Thus, LXXLL motifs do not seem to play a major role in transcriptional activation of the pS2 promoter via the AP1 motif.
Discussion
Two different findings encouraged us to examine the function of the AP1 response element located near the ERE in the pS2 promoter. The first was our observation that an inhibitor of the MAPK cascade, the intracellular signal transduction pathway of which may target AP1 response elements on DNA, was able to block estrogen stimulation of the pS2 gene (Fig. 2) . Second, a previous report demonstrated, with photocross-linking experiments using a fragment of the pS2 promoter and protein extracts from MCF-7 cells, the participation of both ER␣ and a c-fos related protein in two multiprotein complexes associated with the promoter segment that spans the ERE (Schuh and Mueller, 1993) .
We have studied the regulation of the pS2 gene in HepG2 cells. The investigation was focused on the role of ER␣ because ER␤ has not been found to be expressed in hepatocytes (Kuiper et al., 1997; Taylor and Al-Azzawi, 2000) . Our parental HepG2 cells lack estrogen receptors; however, stable integration of ER␣ (HepER3) does not seem to have changed the cells except with regard to estrogen response, because HepG2 and HepER3 cells showed identical gene expression profiles in the absence of estrogen when analyzed with a cDNA array displaying more than 1200 genes (data not shown).
Initially, we confirmed that an "AP-1 like" complex also interacts with the pS2 promoter in liver cells. With the use of the electrophoretic mobility shift assay, a specific complex that immunologically resembles AP1 was formed using a nuclear extract of HepER3 cells and an oligonucleotide that spans the AP1 motif of the pS2 promoter (data not shown). For some concentrations, error bars are not visible because they were smaller than the symbol. E, ERE sequences of the pS2-ALP and the pS2(EREvit)-ALP, respectively. The ERE half-sites are capitalized and nucleotides that differ from the EREvit are underlined.
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We dissected the contribution of the ERE and the adjacent AP1 response element, respectively, in response to estrogen (Fig. 4) . That both a mutated ERE and an AP1 site, respectively, blunted the pS2 response to the synthetic estrogen moxestrol told us two things: that both sites play an important role in pS2 expression in response to estrogens and that the AP1 element plays a dominant role in the regulation of pS2 gene expression in HepG2 cells.
By fusion of a strong activation domain (VP16) to ER␣, we showed that ER␣ was able to interact not only with the ERE but also somehow with the AP1 motif in the context of the pS2 promoter (Fig. 7) . Furthermore, cotransfection of ER␣ devoid of its A/B domain demonstrated that this construct was able to stimulate the pS2 promoter in response to estrogen but that the stimulatory effect was dependent on an intact AP1 motif. A potential explanation could be that the LBD domain of ER␣ is able to interact directly or indirectly with factors at the AP1 element, which results in the significant potentiation of the transcriptional response of the pS2 promoter (Fig. 8, A and B) . Conflicting data exist regarding whether LBD of ER␣ interacts directly with different components of the AP1 complex (Webb et al., 1995; Teyssier et al., 2001) . However, the p160 coactivator SRC-1 has been shown to interact with both c-jun and c-fos (Lee et al., 1998) . The c-jun and c-fos binding sites were shown to be localized in the C-terminal subregion of SRC-1. Thus, SRC-1 may constitute a potential bridging factor between the AP1 motif and ER␣ bound to the ERE by its LXXLL motif interacting with AF-2 of ER␣ and via its C-terminal region with the AP1 complex.
The observation that a larger amount of the GAL4DBD-LXXLL-peptide fusion expression vector was required to disrupt ER␣-mediated transcriptional activity on the pS2 promoter in the presence of an intact AP1 motif may further support the assumption that a p160 coactivator protein is involved in the interplay between the AP1 motif and the ERE (Fig. 9B) . A potential mechanistic explanation could be that an interaction between a protein factor at the AP1 motif and the p160 coactivator has a stabilizing effect on the interaction between the AF-2 of ERE-bound ER␣ and the LXXLL motif of the coactivator. Furthermore, as shown in Fig. 6 , the presence of an intact AP1 motif had a significant effect on the potency of moxestrol, increasing it by 10-fold. It has recently been shown that an elevated concentration of the coactivator SRC-1 in cells caused an increase in the potency of estradiol (Gee et al., 1999) , explained by coactivator-mediated stabilization of the ER-ligand complex. Perhaps the AP1 motif of the pS2 promoter functions in a similar manner; i.e., an interaction between protein factors at the AP1 motif and ER␣ on the ERE, via a coactivator, causes a similar decrease in the off rate of moxestrol and thus an enhanced potency in the transcriptional response to moxestrol. In addition, the type of ERE in the pS2 promoter had a significant effect on its activity (Fig. 6) and it is therefore possible that the presence of the AP1 motif also affects the strength of the ER/ERE interaction. Thus, the presence of the AP1 motif in the pS2 promoter may enhance the transcriptional activity in response to estrogen in several possible ways. Perhaps the potentiation of the pS2 promoter activity that originates at the AP1 motif, is a result of a combination of events that results in an additive or synergistic effect on the transcriptional response to estrogen.
The MAPK pathway is well known to converge on AP1 response elements (Karin, 1995; Duan et al., 2001) . That an inhibitor of PI3K also blocked the estrogen effect on the pS2 gene is consistent with previous reports that have documented inhibition of the MAPK pathway by pharmacological inhibitors of PI3K, suggesting that MAPK may serve as a downstream effector of PI3K (Marra et al., 1995) . However, the nature of the exogenous signal that, in the present study, stimulates the PI3K and MAPK pathways and eventually converges on the AP1 motif of the pS2 gene promoter is intriguing. A body of evidence suggests the existence of a plasma membrane estrogen receptor (Pappas et al., 1995; Razandi et al., 1999) . We have been unable, however, to demonstrate rapid activation of the MAPK pathway in response to estrogen, suggesting that activation of the pS2 gene is probably not mediated via a cell membrane ER. We favor instead a model in which serum factors present in cell me- dium stimulate intracellular signal transduction pathways, including the MAPK pathway, resulting in maintenance of a basal AP1 level sufficient to potentiate the transcriptional activity of the pS2 promoter in response to estrogen.
ER␣ seems to constitute a key factor also in ligand-independent stimulation of the pS2 gene because PMA had a substantially reduced activity in the absence of ER␣ (Fig.  1B) . Furthermore, such antagonists as ICI 164,384, tamoxifen, and raloxifene (Figs. 1D and 5, and data not shown) suppressed the stimulatory activity of moxestrol and PMA alone or in combination. Ligand-independent ER␣ action has been studied extensively and shown to be associated with MAPK-dependent phosphorylation of serine 118 in the AF-1 of ER␣ (Kato et al., 1995) . However, transient transfections of serine 118 mutated ER␣ demonstrated that this mutant and the wild-type ER␣ responded equally well to PMA in stimulating the pS2 promoter reporter gene (data not shown). Recently, it was demonstrated that the PI3K dependent pathway may act directly on ER␣ by phosphorylation of serine 167 in the N-terminal part of the receptor, resulting in increased activity of the ligand-independent AF-1 function (Campbell et al., 2001) . We therefore cannot exclude that serines other than serine 118 of ER␣ have been phosphorylated in the HepER3 cells, which may explain the ligandindependent involvement of ER␣ in the regulated expression of the pS2 gene. Moreover, PMA was shown to mediate its effect primarily via the AP1 element of the pS2 promoter (Fig. 3B) . In contrast to estrogen, PMA was able to stimulate the transcriptional activity of the pS2 promoter in the absence of an intact ERE. Taken together, ER␣ seems to have an indispensable role in the activation process through the AP1 motif because tamoxifen blocked PMA-stimulated reporter gene activity also in the absence of a functional ERE (Fig. 5) . Thus, ER␣ may enhance ligand-independent pS2 transcription in a serine 118-and ERE-independent fashion.
One exciting but speculative mechanism could be that ER␣ activated ligand independently enhances stimulation of pS2 gene expression by participating in the transcriptionally active complex that targets the AP1 motif. The capability of the VP16ER␣ chimera to stimulate transcription via the AP1 element indicates that ER␣ somehow may interact with the AP1 motif (Fig. 7) . ER has been proposed previously to serve as a coactivator for the transcription factor Islet-1 (ISL1) in certain promoter contexts containing ISL1 binding sites (Gay et al., 2000) . Thus, ER␣ may function as a coactivator at transcriptional activation of the pS2 gene via the AP1 motif in response to such factors as PMA. A similar role for ER has been suggested at estrogen induction of the collagenase gene that is mediated through an AP1 response element in its promoter region (Webb et al., 1995) . However, the AP1 sites of the collagenase-and pS2-promoters seem to be functionally different because the pS2 promoter is unresponsive to estrogen via its AP1 motif in the absence of an intact ERE (Fig. 4) . Moreover, tamoxifen and raloxifene are potent activators of the collagenase gene (Webb et al., 1998) , whereas they function as pure antagonists at the AP1 site of the pS2 gene (Barkhem et al., 1997; Fig. 5 ). However, the discrepancy between estrogen and such effectors as PMA in the mode of signaling via the AP1 motif of the pS2 promoter is intriguing. Perhaps it could be explained by differences in the pattern of post-translational modifications of ER␣ and/or cofactors induced by estrogen and PMA, respectively.
We believe that our data on the functional interaction between the ERE and AP1 response element in the pS2 promoter-reporter constructs reflect what would be observed on the endogenous pS2 promoter. The presence of an intact AP1 response element in the pS2 promoter dramatically potentiated the estrogen-induced expression of the pS2 promoter-reporter in HepG2 cells, both when ER␣ was transiently overexpressed (Fig. 6 ) and in HepG2 cells (HepER3) stably transformed to express physiological levels of ER␣ (Fig. 4) . Furthermore, PMA was a more efficacious activator of the endogenous pS2 gene than moxestrol in HepER3 cells (Fig.  1A) , which was also the case when the effect of PMA or moxestrol was assessed at transient transfections of the pS2 promoter-reporter (Fig. 5) . In fact, the relative difference in amplitude between the PMA and moxestrol responses observed on the endogenous pS2 gene was almost identical to the relative difference between the responses evoked by PMA and moxestrol on the pS2 promoter-reporter (Figs. 1A and 5) , supporting the notion that the activity of the pS2 promoterreporter reflects the correct characteristics of the endogenous pS2 gene.
In conclusion, and in accordance with the proposed model (Fig. 10) , the data presented indicate that ER␣ plays a crucial role in mediating the effect not only of estrogen but also of PMA and that the AP1 motif in the pS2 promoter is an essential target on DNA through which various signals converge to modulate pS2 gene expression in the HepG2 cells. Fig. 10 . Putative model for estrogen or PMA activation of the pS2 promoter. Estrogen stimulation of the pS2 promoter required both the ERE and the AP1 motif, indicating a cross-talk between factors at these motifs. The use of selective inhibitors suggested that MAPK and PI3K are necessary for maximal effect of estrogen on the pS2 promoter. We propose that estrogen induction is a result of synergism between the classical ER/ERE pathway and the MAPK pathway that converge on the AP1 motif. The PMA effect was mediated by PKC and shown to act exclusively via the AP1 response element in the pS2 promoter. However, the PMA response seems to be complex and may also involve MAPK, PI3K, and alternative pathway(s). ER␣ is capable to interact with factors at the AP1 motif and contributes substantially to the transcriptional response mediated by PMA via the AP1 response element. 
